Viewing Study NCT05262335


Ignite Creation Date: 2025-12-24 @ 10:36 PM
Ignite Modification Date: 2026-01-01 @ 8:54 PM
Study NCT ID: NCT05262335
Status: UNKNOWN
Last Update Posted: 2023-11-28
First Post: 2022-02-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)
Sponsor: Ruijin Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module